Hit Discovery Constance GmbH: a New European Hub for HTS and Compound Management


Today Hit Discovery Constance GmbH ("HDC"), a new joint venture organisation between Lead Discovery Center (Dortmund/Germany), Centre for Drug Design and Discovery (CD3, KULeuven, Leuven/Belgium) and Axxam (Milan/Italy) has started its operation.

Dortmund (I-Newswire) January 15, 2014 - Today Hit Discovery Constance GmbH ("HDC"), a new joint venture organisation between Lead Discovery Center (Dortmund/Germany), Centre for Drug Design and Discovery (CD3, KULeuven, Leuven/Belgium) and Axxam (Milan/Italy) has started its operation. The new company is based in Constance (Germany) and will make use of the already established equipment and know-how of the former Takeda/Nycomed/Altana screening and compound management facilities at the site.

HDC is a service oriented company which provides high quality drug discovery research services to the Life Science industry and academic or research institutions.

The offering includes assay development, High Throughput Screening ("HTS") using radiometric formats, as well as conventional biochemical and cellular assay formats, automated High Content Screening ("HCS") and Biosafety level 2 (BSL2) HTS. HDC's labs are equipped with three state-of-the-art screening stations, a Screening Collection of 240.000 compounds and offer a REMP-based compound storage & handling facility which allows high quality storage and high throughput compound picking activities. Combined with Axxam`s already established HTS services and compound storage facilities, HDC represent one of the largest screening hubs worldwide.

Stefan Lohmer, Chief Executive Officer at Axxam, commented "today`s opening of HDC, excellently positioned in the middle of Europe, is a further important strategic expansion for our service business, perfectly complementing our existing offers by providing the next level of compound management combined with fully automated Radiometric and High Content Screening, thereby responding to the increasing demands for these screening technologies. Now for all the different targets of interest, the most suitable assay format can be chosen, developed and screened".

"The availability of such HTS and compound management hub also for academic and translational research activities is a significant step forward for the European research community and will boost drug discovery and chemical biology programs significantly in terms of timelines as well as the quality of the hit compounds identified in a screening operation. We are very happy to revive this research site in Constance which has a long-standing history in successful drug discovery", added Bert Klebl, Managing Director at LDC.

Patrick Chaltin, Managing Director at CD3, is very pleased with the collaborative effort and joint venture spirit between the partners which has led to the establishment of the HDC. "With HDC, a new fully automated HTS centre is available for industry as well as for academic and research institutions which can become an important player in the increasing translational drug discovery efforts".

About Lead Discovery Center

Lead Discovery Center (LDC) is a translational drug discovery company which takes on promising early-stage projects and collaboratively transforms them with its academic partners into innovative pharmaceutical leads with proof-of-concept in animal.

LDC sustains a preferred partnership with the Max Planck Society and has formed alliances with AstraZeneca, Bayer and Merck Serono as well as leading academic drug discovery centres around the globe. For more information: www.lead-discovery.de.

About CD3

The Centre for Drug Design and Discovery (CD3) is a technology transfer platform and investment fund focusing on the discovery and development of innovative medicines for all kinds of diseases. By providing the necessary drug expertise and financial resources, CD3 ensures that biomedical research carried out by universities and small biotech companies is translated into starting points for promising new medicines. Subsequently, such new potential medicines can then be further developed by pharma or biotech industry or can form the basis for the establishment of new biotechs. CD3 was set up at the end of 2006 by KU Leuven Research & Development and the European Investment Fund (EIF). For more information: www.cd3.eu.

About Axxam

Axxam is a privately owned contract research and discovery company. The Company has developed a proven track record as a third party research and discovery services provider for the life science industry, including pharma, biotech, crop protection, animal health, cosmetics and nutrition. In addition, Axxam conducts several drug discovery programs for selected targets which are carried out in partnership with other companies or non-profit organizations. For more information: www.axxam.com.

For more information on HDC:

Lead Discovery Center GmbH
Dr. Jan Eickhoff
t: +49 231 9742 7005
e: eickhoff@lead-discovery.de

CD3
Stefaan Allemeersch
t: +32 2 16852602
e: stefaan.allemeersch@cistim.be

Axxam SpA
Dr. Doris Hafenbradl
t: +39 02 2105680
e: doris.hafenbradl.dh@axxam.com

Press contact:

Mr. Jan Eickhoff
Lead Discovery Center GmbH
Otto-Hahn-StraŸe 15
44227 Dortmund
Germany
E-Mail: eickhoff@lead-discovery.de
Web: www.lead-discovery.de
Tel: +49 231 9742 7005

###






About Lead Discovery Center GmbH

The Lead Discovery Center (LDC), a spin-off company of Max Planck Innovation, was established a nove   More..l approach to capitalize on the potential of excellent basic research for the discovery of new therapies for diseases with high medical need. Find more information at: www.lead-discovery.deLess..

Contact Information

Lead Discovery Center GmbH
Thomas Hegendörfer
Otto-Hahn-Straße 15
44227
Phone : 4923197427002

Published in:

Health & Fitness

Published On:

January 15, 2014

Print Release:

Print Release

If you have questions regarding information in this press release contact the company listed above. I-Newswire.com is a press release service and not the author of this press release.The information that is on or available through this site is for informational purposes only and speaks only as of the particular date or dates of that information. As some companies and PR Agencies submit their press releases once per week,month or quarter, make sure to check the official company website for accurate release dates as our site displays the I-Newswire.com press release distribution date only.We do not guarantee the accuracy or completeness of information on or available through this site, and we are not responsible for or omissions in that information or for actions taken in reliance on that information.


Related Releases

Skin Palette Opens Airbrush Suite Inside of The Studio CL.
Rittenhouse, PA. Skin Palette, nationally acclaimed and locally loved, best of Philadelphia sunless bronzing, will open their second state of the art airbrush suite inside The Studio CL Workshop. Top stylist, salon owner and accomplished instructor ,

Doctor Appointment Online Booking
The availability of Online Doctor is now a common phenomenon among users through the site www.meetphysicians.com . This online platform not only provides Doctor Appointment Online but also provides Doctor Consultation. Both the users and the doctors

Cervical Cancer Test Market & Patients - Pap Smear, HPV DNA, VIA - Test & Patients - Worldwide
Renub Research has announced the addition of the "Cervical Cancer Test Market & Patients - Pap Smear, HPV DNA, VIA - Test & Patients - Worldwide" report to its offering

Using The Best Advice To Get In Shape
If you want to improve your muscle quickly, you have to ramp in the weight you make use of in your resistance workout routines. It is because you will only develop muscles once you practical experience a level of level of resistance which is a new co

Supplement Website Claims to Debunk and Demystify the World of Health and Fitness Supplements
"Supplement Critique" offers unbiased, real-world testing of supplement claims for weight loss, fitness and male enhancement supplements.